[Comparison of aprindine (AC 1802) and lidocaine by intravenous route during the acute phase of myocardial infarct].
D000814:Aniline Compounds; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000517:prevention & control*; D001919:Bradycardia / Q000209:etiology / Q000517:prevention & control; D005117:Cardiac Complexes, Premature / Q000209:etiology / Q000517:prevention & control; D004048:Diethylamines; D004562:Electrocardiography; D004827:Epilepsy / Q000139:chemically induced; D005260:Female; D006327:Heart Block / Q000209:etiology / Q000517:prevention & control; D006352:Heart Ventricles; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007192:Indenes / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008012:Lidocaine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009203:Myocardial Infarction / Q000150:complications*; D013610:Tachycardia / Q000209:etiology / Q000517:prevention & control
D000814:Aniline Compounds; D000889:Anti-Arrhythmia Agents; D004048:Diethylamines; D007189:Indans; D007192:Indenes; D008012:Lidocaine
Comparaison aprindine (AC 1802)-lidocaine par voie intraveineuse a la phase aiguë de l'infarctus du myocarde